Immunodeficiency News and Research

RSS

Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to fight infectious disease is compromised or entirely absent.

Tocilizumab in Critical COVID-19 Patients

A new study by scientists at Metro Infectious Disease Consultants and published on the preprint server medRxiv* in June 2020 reports that the cytokine blocker tocilizumab is a useful adjunct to supportive medical care in severe COVID-19, with increased survival and a lower requirement for mechanical ventilation.

10 Jun 2020

Protease inhibition could help defeat SARS-CoV-2

As the COVID-19 pandemic caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to spread around the world, many researchers are studying epidemiological models to predict its propagation. As of yet, there are no effective vaccines that could counter the SARS- CoV-2 infection or drugs to treat COVID-19 disease

9 Jun 2020

Octapharma extends support for COVID-19 study following promising preliminary data

Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.

3 Jun 2020

CSL Behring and Seattle Children's partner to develop gene therapies for primary immunodeficiency diseases

Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

2 Jun 2020

Studies call for reforms to improve nutritional programs in HIV care settings

HIV management in developing countries varies with socioeconomic and structural circumstances, with two Flinders University studies finding examples of key ways to close the gap for those worst affected in developing countries.

1 Jun 2020

Low albumin levels could predict poor outcome in COVID-19

A Spanish study has revealed that COVID-19 patients who have a low level of albumin have a poorer outcome compared to those with normal levels of blood albumin. The study titled, “Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: a retrospective cohort study,” was released prior to peer-review on the open-access preprint server site Medrxiv*.

13 May 2020

Study reveals antiviral properties of glycosaminoglycans against SARS-CoV-2

Glycosaminoglycans can inhibit cell invasion by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses, which supports the utilization of such therapeutics in the fight against coronavirus disease (COVID-19) – reports a new study available on the preprint server bioRxiv.

3 May 2020

Racial inequalities in liver cancer mortality increased after introduction of hepatitis C drugs

In the United States, hepatocellular or liver cancer deaths have doubled since 1979. Hepatitis C virus is the leading cause of liver cancer.

30 Apr 2020

New database catalogs peptides that may halt SARS-CoV-2 cell infection

In the quest for a highly specific and tailored treatment strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recent publication available on the preprint server bioRxiv describes a repository of designed peptides that interfere with the early stages of viral invasion process.

30 Apr 2020

Boston Children's Hospital launches two-pronged study of COVID-19 in children

Boston Children's Hospital has launched a two-pronged study of COVID-19 disease among children and youth up to age 25 across the country, with $2.1 million in funding from the Centers for Disease Control and Prevention.

28 Apr 2020

Using neutralising antibodies in the fight against COVID-19

While many scientists and pharmaceutical companies are racing to develop a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, there is also an urgent need for a coronavirus disease (COVID-19) treatment. The potent virus has now spread to 210 countries and territories, affecting more than 3.04 million people. Now, a team of German scientists is working on using antibodies to prevent and treat COVID-19.

27 Apr 2020

Breakthrough discovery in HIV research opens path to new, better therapies

New research on the human immunodeficiency virus (HIV) structure has revealed a promising novel drug target for treating it.

23 Apr 2020

COVID-19 and immunodeficiency

COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly infectious disease. As of today, over 170,000 people worldwide have succumbed to the infection. Reports have shown that some comorbidities and illnesses raise the risk of getting infected and also influence the severity of the disease. Having a compromised immune system can also drastically raise the risk of getting COVID-19.

21 Apr 2020

Octapharma USA supports new COVID-19 clinical trial

Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, M.D. of Sharp Memorial Hospital in San Diego, California focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator dependent.

16 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020

Ebola drug effective against key enzyme of coronavirus that causes COVID-19

Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.

13 Apr 2020

Exploring mechanisms of resistance to HIV in people with sickle cell disease

Analysis supports reports that sickle cell disease causes lower HIV infection rate, but cell studies did not reveal a mechanism.

8 Apr 2020

How do viruses mutate and jump to humans?

Zoonotic spillover events like the current novel coronavirus pandemic present threats to human health. But what is zoonotic spillover and how do they occur?

7 Apr 2020

Antiparasitic drug Ivermectin kills coronavirus in 48 hours

Around the world, scientists race to develop a vaccine or treatment against the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, a team of researchers has found that a drug already available around the world can kill the coronavirus in a lab setting in just 48 hours.

6 Apr 2020